/Kioko287342.html,Gold-plated,Men's,Yellow,Diamond,Jewelry & Watches , Other Jewelry,Gold,JB-6225,562,Dial,Watch,modniznacky.cz,JBW,$75 $75 JBW 562 Diamond Gold Dial Yellow Gold-plated Men's Watch JB-6225 Jewelry & Watches Other Jewelry /Kioko287342.html,Gold-plated,Men's,Yellow,Diamond,Jewelry & Watches , Other Jewelry,Gold,JB-6225,562,Dial,Watch,modniznacky.cz,JBW,$75 JBW gift 562 Diamond Gold Dial Watch Gold-plated Yellow JB-6225 Men's JBW gift 562 Diamond Gold Dial Watch Gold-plated Yellow JB-6225 Men's $75 JBW 562 Diamond Gold Dial Yellow Gold-plated Men's Watch JB-6225 Jewelry & Watches Other Jewelry

JBW gift 562 Diamond Gold Dial Watch Gold-plated Yellow JB-6225 New mail order Men's

JBW 562 Diamond Gold Dial Yellow Gold-plated Men's Watch JB-6225

$75

JBW 562 Diamond Gold Dial Yellow Gold-plated Men's Watch JB-6225

|||

Item specifics

Condition:
Pre-owned:
An item that has been used or worn previously. See the seller’s listing for full details and description of any imperfections.
Seller Notes:
“Pre-owned: An item that has been used previously. The item may have some signs of cosmetic wear, but is fully operational and functions as intended. This item may be a floor model or store return that has been used. Like new, little to no cosmetic wear/scratches. Face and dial in great condition. Light scratches to back. Functions properly. All watches come only as pictured. A3830”
Handmade:
No
Country/Region of Manufacture:
Unknown
Department:
Men
Base Metal:
Gold
Material:
Crystal
Personalize:
No
Type:
Watch
Antique:
No
Main Stone Color:
Yellow
Color:
Yellow
Vintage:
No
MPN:
Does Not Apply
Main Stone:
Diamond
Wholesale:
Yes
Metal:
Stainless Steel
Brand:
JBW





JBW 562 Diamond Gold Dial Yellow Gold-plated Men's Watch JB-6225

CURRENT ISSUE
May, 2022

No. 107 (5)

2020 Impact Factor: 9.941 Submission > Acceptance: 80 days
ARTICLES IN THREE SENTENCES
Article

Germline GATA2 variant disrupting endothelial eNOS function and angiogenesis can be restored by c-Jun/AP-1 upregulation

Germline GATA2 gene variants have been associated with several inherited and acquired hematologic disorders, and thrombosis has been reported in 25% of patients. Authors demonstrated that GATA2 deficiency is associated with defective expression of eNOS by platelets and endothelial cells with impaired NO production, suggesting that this may represent an important thrombogenic mechanism. They also identified a therapeutic option, through atorvastatin, able to restore eNOS expression and angiogenesis in GATA2 deficiency in vitro.

Giulio Purgatorio et al.

Letter

SF3B1-mutant myelodysplastic syndrome/myeloproliferative neoplasms: a unique molecular and prognostic entity

This study includes all consecutive WHO-defined MDS/MPN patients of Mayo Clinic from 1994 to 2020.Next-generation sequencing information at diagnosis was available for 444 (57%) patients. Authors combined all SF3B1-mutant MDS/MPN patients into one category (n=78) and compared them to their wild-type counterparts (n=446). Leukemia-free survival and overall survival in MDS/MPN patients with SF3B1 mutations were significantly better compared to SF31B wild-type MDS/MPN patients.

Abhishek A. Mangaonkar et al.

Article

Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter cohort study

Data regarding efficacy and toxicity of CAR-T cell therapy in the elderly, geriatric population are insufficient. This study explored the characteristics and outcome of 47 consecutive patients, 70 years or older, referred for CAR-T. The outcomes of CAR-T cell therapy are comparable between elderly, geriatric and younger patients, indicating that age as per se should not preclude CAR-T cell administration.

Ron Ram et al.

Article

Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma

In this prospective pilot study, authors evaluated a rituximab/prednisone prephase treatment strategy in 33 older, vulnerable patients with newly diagnosed DLBCL. This prephase therapy was feasible with acceptable toxicity profiles and excellent long-term survival. Prephase therapy with rituximab/prednisone should be considered for all older, vulnerable DLBCL patients prior to curative intent, anthracycline-based chemoimmunotherapy.

Richard J. Lin et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA